Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2023-10-25 Interim / Quarterly Rep…
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
2023年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2023 Third Quarter Report" of Beijing Northland Biotechnology Co., Ltd. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial changes for the period ending September 30, 2023. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the nine months and the third quarter of 2023. It is unaudited but contains substantive financial data and management explanations. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2023
2023-10-25 Chinese
第六届监事会第五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Beijing Northland Biotechnology Co., Ltd. regarding the review and approval of the company's 2023 third quarter report. It includes details about the meeting, attendance, and the Supervisory Board's opinion on the quarterly report. The document does not contain the actual financial statements or substantive financial data of the quarterly report itself but refers to the report published elsewhere (announcement number 2023-096). The document is short (1060 characters) and serves as an official announcement of the Supervisory Board's review and approval of the interim report, not the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a formal disclosure related to corporate governance and compliance rather than the Interim/Quarterly Report (IR) which requires actual financial data.
2023-10-25 Chinese
第六届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Beijing Northland Biotechnology Co., Ltd. It details the convening and attendance of the sixth board meeting, including the approval of the 2023 third quarter report. The document references the actual third quarter report being disclosed on the Beijing Stock Exchange information platform but does not contain the financial data or substantive analysis itself. The document is short (864 characters) and serves as an announcement of the board meeting decisions rather than the report itself. Therefore, it fits best under Board/Management Information (MANG) as it announces board meeting resolutions and approvals.
2023-10-25 Chinese
关于股东所持公司股票自愿限售的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding voluntary stock lock-up by shareholders, detailing the number of shares voluntarily restricted from trading, the shareholders involved, and the terms of the lock-up period. It includes tables of shareholding details and commitments by key shareholders and executives. There is no financial performance data, earnings information, or regulatory filings about financial results. The document is a formal announcement about share restrictions and shareholder commitments, which fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like Director's Dealing or Share Issue/Capital Change. The document length is short (2520 characters), and it is not a report or a presentation but an announcement of a corporate action related to share restrictions.
2023-10-08 Chinese
北京海润天睿律师事务所关于北京诺思兰德生物技术股份有限公司2023年第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, attendance, and voting procedures of a company's 2023 second extraordinary general meeting (临时股东大会). It details the legality and compliance of the meeting process, attendance, and voting results. The document does not contain financial statements or detailed financial performance data, nor is it a report of the meeting itself or a presentation. It is a legal opinion related to a shareholders' meeting, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 2048 characters, which is relatively short but contains substantive content about the voting results and meeting legality, not just an announcement of a report publication. Therefore, the best fit is DVA.
2023-09-11 Chinese
2023年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2023 second extraordinary general meeting of shareholders of Beijing Northland Biotechnology Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the announcement of voting results from the shareholders' meeting rather than the meeting materials or the full report itself. The document length is short (1653 characters), and it is clearly a resolution announcement with voting outcomes. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-09-11 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.